Table 5.
Manufacturing (choice of agents(s) to confer tolerogenicity) |
Cell dosage |
Timing/frequency of cell infusion |
Relevance of Ag pulsing |
Migratory abilities and relevance (depending on the site of administration) |
Longevity; fate of donor MHC gene products |
Potential reprogramming under inflammatory conditions |
‘Appropriate’ immunosuppressive agents/regimen |
Overcoming immunologic memory |
Comparison with other types of regulatory immune cell therapy (e.g. Treg) |
Cost |